Observation on the clinical effect of dapagliflozin in patients with type 2 diabetes mellitus and coronary heart disease
Objective To observe the clinical effect of dapagliflozin in patients with type 2 diabetes mellitus and coronary heart disease.Methods A total of 180 patients with type 2 diabetes mellitus and coronary heart disease were divided into a reference group and a study group according to random number table method,with 90 patients in each group.The reference group was treated with acarbose on the basis of standard coronary heart disease treatment,and the study group was treated with dapagliflozin on the basis of standard coronary heart disease treatment.Patients in both groups were compared in terms of levels of blood glucose indexes(glycosylated hemoglobin,fasting blood glucose,2 h postprandial blood glucose),blood lipid indexes(triglyceride,serum total cholesterol,low density lipoprotein cholesterol,high density lipoprotein cholesterol),inflammatory factors(C-reactive protein,interleukin-6,interleukin-8)before and after treatment,and adverse cardiovascular events.Results After treatment,the study group had glycosylated hemoglobin of(5.02±1.29)%,fasting blood glucose of(6.03±1.34)mmol/L,and 2 h postprandial blood glucose of(8.08±1.05)mmol/L,which were lower than(7.54±1.31)%,(7.02±1.59)mmol/L and(9.13±1.24)mmol/L in the reference group,and the difference between groups was statistically significant(P<0.05).After treatment,the study group had triglyceride of(1.36±0.27)mmol/L,serum total cholesterol of(4.15±1.01)mmol/L,and low density lipoprotein cholesterol of(2.26±0.39)mmol/L,which were lower than(1.94±0.43),(5.05±1.08),and(3.21±0.78)mmol/L in the reference group;the study group had higher high density lipoprotein cholesterol of(1.59±0.67)mmol/L than(1.08±0.56)mmol/L in the reference group;the difference between groups was statistically significant(P<0.05).After treatment,the study group had C-reactive protein of(5.95±1.28)mg/L,interleukin-6 of(9.34±1.51)ng/L,and interleukin-8 of(76.21±10.34)pg/ml,which were lower than(8.76±1.78)mg/L,(16.04±2.46)ng/L,and(83.12±10.75)pg/ml in the reference group,the difference between groups was statistically significant(P<0.05).In the course of treatment,the incidence of adverse cardiovascular events in the study group was 4.44%,which was lower than 17.78%in the reference group,and the difference between groups was statistically significant(P<0.05).Conclusion Dapagliflozin has good clinical effect in the treatment of patients with type 2 diabetes mellitus and coronary heart disease,which can effectively adjust various clinical indicators of patients,delay the development of disease and improve safety.
Type 2 diabetes mellitusCoronary atherosclerotic heart diseaseDapagliflozinClinical effect
NETL
NSTL
万方数据
